A Study of SL-325 in Participants With Hidradenitis Suppurativa
A legfontosabb adatok
- Fázis
- 2. fázis
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Shattuck Labs, Inc.
- Azonosító
- NCT07934017
- A regiszteradat frissítve
- 2026. november 12.
- Eredeti leírás
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa.A teljes eredeti leírásKevesebb
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderate to Severe Hidradenitis Suppurativa (RECEPTIVE-HS1)
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa.
The study consists of a screening period of up to 5 weeks, a 16-week primary treatment period, 36-week extension period, and a follow-up period of up to 12 weeks.
Bevonási feltételek: A clinical diagnosis of HS at Screening as assessed by the Investigator; Signs and symptoms of HS for ≥6 months prior to Screening; ≥5 total AN count; HS lesions present in ≥2 distinct anatomical areas; ≥1 anatomic area of HS involvement characterized as Hurley Stage II or III; Draining tunnel count of ≤20; Inadequate response or recurrence of disease activity after an appropriate course of systemic antibiotics for the treatment of HS OR intolerance or contraindication to systemic antibiotics for the treatment of HS.
Kizáró feltételek: Prior exposure to any anti-DR3 or anti-TL1A agent or agent with an anti-DR3 or anti-TL1A component; Evidence of other active skin disease or condition that could, in the Investigator's opinion, interfere with the evaluation of HS; Active tuberculosis (TB) or inadequately treated latent tuberculosis infection (LTBI).